Pediatric Hematology/Oncology Overview

The Division of Pediatric Hematology/Oncology faculty are conducting cutting-edge basic, translational, and clinical cancer and hematology research aimed at understanding the fundamental mechanisms that lead to malignancy, as well as developing novel treatment strategies for childhood malignancy. Research areas include: the regulation of cell proliferation by intracellular signaling; tumor suppression in acute leukemia; the regulation of cellular senescence; accelerated drug discovery; immunotherapy for malignant diseases, and Phase I and II trials for malignant diseases.

The Division of Pediatric Hematology/Oncology participates in clinical trials through the Children's Oncology Group (COG) and the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).

Research faculty are internationally renowned physician-scientists. Research is supported by the National Institutes of Health, Four Diamonds, and other philanthropic organizations.

Founded in 1996, the Four Diamonds Pediatric Cancer Research Center is creating new knowledge to save the lives of children with cancer. Four Diamonds' outstanding physician-scientists, scientists, and their teams are focused on learning more about how cancer forms, how it can be treated, and how treatments can be made to be more effective while minimizing the long-term side effects. With membership in leading national research consortiums, the Children's Hospital is able to offer Phase I, Phase II, and Phase III state-of-the-art clinical trials to pediatric cancer patients and to children who relapse in the course of their care, opening up novel treatment avenues for our sickest patients.